Review article · 2025 · Open access

Platelet activation, aspirin, and cancer: From basic science to clinical trials

Carlo Patrono, John Burn, Paola Patrignani, Ruth Elizabeth Langley

Pharmacological Reviews, 78(1), 100109 · Published 3 December 2025 · DOI 10.1016/j.pharmr.2025.100109

Open full textCite this paper

In brief

“Platelet activation, aspirin, and cancer: From basic science to clinical trials” is a 2025 review article by Carlo Patrono and 3 co-authors, published in Pharmacological Reviews. OpenAlex counts 17 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmacological Reviews.

Citations
17
Most cited in
2026 (17)
Field-weighted impact
1.55
References
163
Authors
4

Abstract

There is extensive evidence that aspirin prevents cancer, but the mechanism of action is uncertain. Once-daily low-dose aspirin (75–100 mg) completely and permanently inactivates the cyclooxygenase (COX) activity of prostaglandin G/H synthase-1 (COX-1) in platelets, suppressing thromboxane (TX)A 2 -dependent platelet activation. In this article, we review the mechanistic links between platelet activation, inflammation, cancer development, and progression and summarize recent clinical trial results and associated biomarker studies. We hypothesize that persistently enhanced platelet activation has 2 distinct tumorigenic consequences mediated by the release of TXA 2 : (1) at sites of gastrointestinal mucosal lesions, it promotes a local inflammatory response with COX-2 induction and enhanced prostaglandin E 2 biosynthesis, contributing to early events in carcinogenesis; (2) it inhibits T-cell immunity to cancer by the activation of TXA 2 receptors in lymphocytes, promoting cancer progression and metastasis dissemination. Supporting these hypotheses, abnormal and persistent platelet activation has been demonstrated in patients recently diagnosed with cancer and in those with adenomatous colonic polyps. To date, most clinical trials evaluating aspirin have focused on either primary cancer prevention, metastasis prevention (adjuvant treatment), or cardiovascular prevention. For an individual, benefits may accrue from one (or all) of these areas, and they collectively need to be balanced against bleeding risk. Collating large clinical datasets for meta-analysis alongside mechanistic studies will inform the interpretation of clinical trials, with the aim of identifying individuals most likely to benefit from aspirin. Significance Statement We reviewed the experimental and clinical evidence supporting a previously unrecognized role of platelet activation in both the early stage of colorectal carcinogenesis and in cancer progression and metastasis. The findings support the use of low-dose aspirin in cancer prevention and treatment. Data from large randomized clinical trials support the use of aspirin for the prevention of Lynch syndrome cancers and in the adjuvant setting for patients with colorectal cancer whose tumors have a mutation in the phosphatidylinositol 3-kinase pathway genes. Although thromboxane A 2 –dependent platelet activation is the most thoroughly investigated mechanism and the established drug target of the antiplatelet effect of low-dose aspirin, it seems biologically plausible that other pathways of platelet activation, such as the ADP-P2Y 12 pathway, may play a similar and possibly complementary role.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Patrono, C., Burn, J., Patrignani, P., & Langley, R. E. (2025). Platelet activation, aspirin, and cancer: From basic science to clinical trials. Pharmacological Reviews, 78(1), 100109. https://doi.org/10.1016/j.pharmr.2025.100109

MLA 9

Patrono, Carlo, et al. “Platelet activation, aspirin, and cancer: From basic science to clinical trials.” Pharmacological Reviews, vol. 78, no. 1, 2025, p. 100109. https://doi.org/10.1016/j.pharmr.2025.100109.

Chicago

Patrono, Carlo, John Burn, Paola Patrignani, and Ruth Elizabeth Langley. 2025. “Platelet activation, aspirin, and cancer: From basic science to clinical trials.” Pharmacological Reviews 78 (1): 100109. https://doi.org/10.1016/j.pharmr.2025.100109.

Harvard

Patrono, C. et al. (2025) ‘Platelet activation, aspirin, and cancer: From basic science to clinical trials’, Pharmacological Reviews, 78(1), p. 100109. doi:10.1016/j.pharmr.2025.100109.

IEEE

C. Patrono, J. Burn, P. Patrignani, and R. E. Langley, “Platelet activation, aspirin, and cancer: From basic science to clinical trials,” Pharmacological Reviews, vol. 78, no. 1, p. 100109, 2025, doi: 10.1016/j.pharmr.2025.100109.

BibTeX

@article{patrono2025platelet,
  title     = {{Platelet activation, aspirin, and cancer: From basic science to clinical trials}},
  author    = {Patrono, Carlo and Burn, John and Patrignani, Paola and Langley, Ruth Elizabeth},
  journal   = {Pharmacological Reviews},
  year      = {2025},
  volume    = {78},
  number    = {1},
  pages     = {100109},
  doi       = {10.1016/j.pharmr.2025.100109},
  url       = {https://doi.org/10.1016/j.pharmr.2025.100109}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects

  • platelet activation
  • low-dose aspirin
  • cancer prevention
  • thromboxane A2
  • cyclooxygenase-1
  • cyclooxygenase-2
  • colorectal carcinogenesis
  • inflammation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Patrono, C., Burn, J., Patrignani, P., & Langley, R. E. (2025). Platelet activation, aspirin, and cancer: From basic science to clinical trials. Pharmacological Reviews, 78(1), 100109. https://doi.org/10.1016/j.pharmr.2025.100109

How many times has this paper been cited?

17 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pharmacological Reviews: sign in and open the full text from this page.

Who wrote this paper?

Carlo Patrono, John Burn, Paola Patrignani, Ruth Elizabeth Langley.

What is the DOI of this paper?

10.1016/j.pharmr.2025.100109, permanently at https://doi.org/10.1016/j.pharmr.2025.100109. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.